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High performance liquid chromatography was coupled with UV detection for simultaneous quantification of lopinavir (LPV) 
and ritonavir (RTV) in human plasma. This assay was sensitive, accurate and simple, and only used 200 µL of plasma sample. 
Samples were liquid-liquid extracted, and diazepam was used as an internal standard. The chromatographic separation was 
achieved on a C18 reversed-phase analytic column with a mobile phase of acetonitrile-sodium dihydrogen phosphate buffer 
(10 mmol L1, pH 4.80) (60:40, v/v). UV detection was conducted at 205 nm and the column oven was set at 40°C. Calibration 
curves were constructed between 0.5–20 μg mL1 for LPV and 0.05–5 μg mL1 for RTV. The relative standard deviations were 
2.16%–3.20% for LPV and 2.12%–2.60% for RTV for intra-day analysis, and 2.34%–4.04% for LPV and 0.31%–4.94% for 
RTV for inter-day analysis. The accuracy was within 100%±10%. The mean extraction recoveries were 79.17%, 52.26% and 
91.35% for RTV, LPV and diazepam, respectively. This method was successfully applied to human plasma samples from pa-
tients orally administered a salvage regimen of lopinavir-ritonavir tablets. 
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Lopinavir (LPV) is a protease inhibitor that has been 
co-formulated with a low dose of ritonavir (RTV) to im-
prove its pharmacokinetic properties, resulting in substan-
tially increased plasma exposure that maintains high drug 
levels throughout a 12-h dosing interval [13]. Lop-
inavir-ritonavir (LPV/r) shows sustained suppression of 
viral replication and durable elevation of CD4+ T cell counts 
in both antiretroviral therapy-naive and -experienced human 
immunodeficiency virus (HIV) infected patients [4,5]. To 
date, LPV/r has been reserved for salvage therapy in coun-
tries with limited HIV treatment resources.  
The relationship between plasma concentrations of pro-
tease inhibitors and antiviral efficacy and/or toxicity has 
been clearly demonstrated [46]. The current guideline 
from the United states Department of Health and Human 
Services (updated December 2009) suggests a target trough 
concentration (Ctrough) of LPV in human plasma of 1 µg 
mL1 [7]. Gutiérrez et al. [8] demonstrated a significant 
correlation between LPV Ctrough and changes in triglyceride 
and cholesterol levels. Patients with grade 2 or higher cho-
lesterol elevation have been found to have a LPV Ctrough at 
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week 4 greater than 8 µg mL1. Therapeutic drug monitoring 
of protease inhibitor is beneficial for identification of 
suboptimal drug exposure, detection of drug-related toxicity, 
and prevention of viral resistance [9,10]. Additionally, be-
cause LPV/r is metabolized by cytochrome P450 enzymes, 
monitoring may be useful for evaluation of drug-drug inter-
actions, such as those with a potent CYP 3A4 inducer or 
inhibitor that has been shown to increase or decrease the 
LPV plasma concentration [11,12]. Finally, the plasma 
concentrations of LPV and RTV are required for pharmaco-
kinetic studies, which may be used to assist in the determi-
nation of the most suitable dosing regimen for each patient. 
Therefore, a simple and sensitive analytical method for 
quantification of LPV and RTV in human plasma is needed. 
Several HPLC methods for simultaneous determination 
of LPV and RTV have been described [1322]. Most of the 
methods using UV detection [15,16,18,20,21] have some 
critical disadvantages, including requirements for gradient 
elution programs, cumbersome operation procedures, bulk 
plasma samples, and multiple wavelengths. These require-
ments make the methods time-consuming and difficult for 
high throughput assays. More recently, HPLC methods 
coupled with mass spectrometry or diode array detection for 
quantitative determination of LPV and RTV have been re-
ported [13,14,22]. However, this technique imposes a high 
requirement for instruments and materials and increases the 
analysis cost, which limits its application in re-
source-limited settings such as China and other developing 
countries. This paper describes a novel method for simulta-
neous quantification of LPV and RTV in a 200 µL plasma 
sample. An optimized liquid-liquid extraction (LLE) pro-
cedure was combined with isocratic elution HPLC and UV 
detection. This method is sensitive, simple, rapid and has 
low requirements for instrumentation and chemical reagents, 
which means it can be used in many situations. 
1  Materials and methods 
1.1  Chemicals and reagents 
LPV (LOT#DH106-070601b) and RTV (LOT#090702) 
standards were generously provided by Shanghai Desano 
Chemical Pharmaceutical Corporation (Shanghai, China). 
Diazepam (internal standard, IS) was purchased from Sig-
ma-Aldrich (St. Louis, MO). Acetonitrile (Honeywell Bur-
dick & Jackson, Morristown, NJ), methanol and methyl 
tert-butyl ether (TEDIA, Fairfield, OH) were of HPLC 
grade. Sodium dihydrogen phosphate (Sinopharm Chemical 
Regent Corporation, Beijing, China) was of AR grade. De-
ionized water was obtained from a Milli-Q ultra-pure water 
system (Millipore, Billerica, MA). 
1.2  Chromatography 
A HPLC system consisting of a LC-20AT pump, a SIL-20A 
autosampler, a SPD-20A UV-Vis detector and a CTO-20A 
column oven (Shimadzu, Kyoto, Japan) was used for this 
experiment. The autosampler was set at 20°C. The analyti-
cal column was a Shimadzu Shim-pack CLC-ODS C18 
column (15 cm×6 mm I.D., 5 µm) with a μBondapak C18 
Guard-pak precolumn (Waters, Milford, MA). The detec-
tion wavelength was 205 nm and the column oven was set 
at 40°C. The chromatographic data were collected by LC 
Solution chromatography system (Scientific Software, Shi-
madzu). 
The mobile phase was a mixture of acetonitrile-sodium 
dihydrogen phosphate (10 mmol L1, pH 4.8) (60:40, v/v). 
The run time was 12 min, and the mobile phase flow rate 
was 1 mL min1. The injection volume was 20 µL. 
1.3  Preparation of calibration standards and quality 
control (QC) samples 
LPV and RTV were dissolved in methanol at concentrations 
of 400 and 100 µg mL1, respectively. Calibration curve 
samples were prepared by spiking fresh blank plasma with 
the LPV and RTV stock solutions to give final concentra-
tions of 20, 16, 12, 8.0, 4.0, 2.0 and 0.5 µg mL1 for LPV 
and 5.0, 4.0, 3.0, 2.0, 1.0, 0.5, and 0.05 µg mL1 for RTV. 
Three QC samples were prepared in plasma at concentra-
tions of 18 (high quality control, HQC), 10 (medium quality 
control, MQC) and 1 µg mL1 (low quality control, LQC) 
for LPV and 4.5 (HQC), 2.5 (MQC), 0.25 µg mL1 (LQC) 
for RTV. The QC samples were used for evaluation of the 
recovery, precision and accuracy of the developed method, 
and the stability of LPV and RTV. When analyzing un-
known samples, the QC samples were analyzed randomly 
along with the unknown samples. A 120 µg mL1 stock so-
lution of the IS, diazepam, was prepared in deionized water 
containing methanol (approximately 10 %). The working IS 
solution (12 µg mL1) was prepared by diluting the stock 
solution with deionized water.  
The calibration, QC, and IS samples were stored at 
–60°C before use.  
1.4  Plasma extraction procedures 
On the day of analysis, the calibration, QC and plasma 
samples were thawed and allowed to equilibrate at room 
temperature. Methyl tert-butyl ether (1 mL) and the diaze-
pam working IS solution (20 µL) were added to 200 µL of 
plasma in a 1.5 mL vial. After vortex mixing (Ping-Pong 
74580, Block Scientific, Bohemia, NY) the sample was left 
for 5 min at ambient temperature. The organic layer was 
evaporated to dryness with highly purified nitrogen, and the 
residue was redissolved in 100 µL of 20 % acetonitrile. The 
resulting solution was carefully vortex mixed and then cen-
trifuged at 3000×g for 5 min (Model 113, Sigma-Aldrich). 
Finally, 20 µL aliquots was injected into the chromato-
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graphic system.  
1.5  Analytic method validation 
Seven-point calibration was constructed by plotting the 
peak height ratios of LPV and RTV to the IS (diazepam) 
against the sample concentrations. Weighted least square 
linear regression (weighting factor: 1/concentration) was 
used because of the large calibration curve range. The cali-
bration curves were used to calculate the LPV and RTV 
concentrations in the QC and unknown samples. 
The absolute recoveries of LPV and RTV and the IS 
from human plasma were determined by comparing the 
peak heights of LPV and RTV and IS in the extracted QC 
samples with those in aqueous solutions at the same con-
centrations. The method recoveries of LPV and RTV from 
plasma samples were measured by comparing the extracted 
QC samples after liquid-liquid extraction with the spiked 
concentrations of LPV and RTV. 
The intra-day and inter-day variability of the low, me-
dium, and high concentration QC samples was used to 
evaluate the precision of the method. The accuracy was 
evaluated by comparing the relative values of the calculated 
concentrations of the QC samples with their theoretical 
values. 
The freeze-thaw stability was determined after three 
freeze-thaw cycles of freezing at –60°C for 24 h and then 
thawing completely at room temperature. The stability of 
extracted samples at 20°C in the autosampler was evaluated 
up to 24 h after extraction. The long-term stability of LPV 
and RTV was evaluated using QC samples that were stored 
at –60°C for at least 3 months. 
1.6  Specificity 
The specificity was determined by analyzing six different 
blank human plasma samples. Interference from twelve 
commonly used and potentially coadministered medications 
was also investigated. These medications included ribavirin, 
fenofibrate, fluconazole, ibuprofen, atorvastatin, the non- 
nucleosides reverse transcriptase inhibitors nevirapine and 
efavirenz, and the nucleosides reverse transcriptase inhibi-
tors lamivudine, didanosine, stavudine, zidovudine and 
tenofovir. For the method to be successfully applied, there 
should be no interference from endogenous or exogenous 
materials at the retention time of the two analytes or IS. 
1.7  Sample collection 
The study was approved by the Ethics Committee of Peking 
Union Medical College Hospital (Beijing, China), and writ-
ten informed consent was obtained from each HIV-positive 
patient in the study. Three Chinese HIV-positive adults 
were orally administered a salvage regimen of one tablet of 
300 mg of tenofovir DF (Viread, Gilead sciences, US) and 
lamivudine (Desano, Shanghai, CN) once daily and two 
tablets of 200/50 mg LPV/r (Kelatra, Abbott, USA) twice 
daily. Good compliance was found at a 48-week follow up. 
After effective antiretroviral treatment, sustained virological 
suppression and favorable immunological response were 
achieved. The patients were not prescribed CYP3A4 inhib-
itors or inducers.  
To measure the trough concentration (Ctrough) blood sam-
ples were collected before the next drug administration, and 
to measure the peak concentration (Cmax) blood samples 
were collected 2 h after administration. All samples were 
collected in tubes coated with spray dried EDTA and cen-
trifuged in the real time to obtain plasma samples, which 
were stored at –60°C until analysis.  
2  Results 
2.1  Chromatograms 
Chromatograms were obtained of an aqueous solution of 
LPV, RTV, and the IS (Figure 1A), a blank plasma sample 
(Figure 1B), standard calibration sample spiked with LPV at 
18 µg mL1 and RTV at 4.5 µg mL1 (Figure 1C), and a hu-
man plasma sample from a patient receiving LPV/r tablets 
(Figure 1D). The retention times of the IS, RTV and LPV 
were 7.566, 8.838 and 9.835 min, respectively.  
2.2  Specificity 
No interfering peaks from endogenous compounds or po-
tential coadministered drugs were observed at the retention 
times of LPV, RTV, or the IS in the chromatograms of six 
different blank plasma samples. 
2.3  Linearity  
The calibration curves were linear from 0.5–20 µg mL1 for 
LPV and 0.05–5 µg mL1 for RTV (n=6). Typical equations 
of calibration curves were Y=0.208X－0.0013 (r=0.9995) 
for LPV and Y=0.198X－0.0009 (r=0.9997) for RTV. The 
lower limit of quantification (LLOQ) of LPV was 0.5 µg 
mL1 and that of RTV was 0.05 µg mL1. 
2.4  Precision and accuracy 
The precision and accuracy of this method were evaluated 
using the HQC, MQC and LQC samples. The intra- and 
inter-day relative standard deviations (R.S.D.s) for LPV 
were 2.16%–3.20% and 2.34%–4.04%, respectively (Table 1). 
For RTV, the intra- and inter-day R.S.D.s were 2.12%– 
2.60% and 0.31%–4.94%, respectively. The accuracies for 
the QC samples were within an acceptable range (±10%).  
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Figure 1  Chromatograms of an aqueous solution of LPV, RTV, and the 
IS (A), a blank plasma sample (B), standard calibration sample spiked with 
LPV at 18 µg mL1 and RTV at 4.5 µg mL1 (C), and a human plasma  
sample from a patient taking LPV/r tablets (D). 
2.5  Recovery 
The absolute recoveries measured with the HQC, MQC and 
LQC samples for RTV were 73.69%, 73.96% and 89.85%, 
respectively, and the mean was 79.17%. The absolute re-
coveries measured with the HQC, MQC and LQC samples 
for LPV were 50.04%, 50.27% and 56.48%, respectively, 
and the mean was 52.26%. The mean extraction recovery 
for the IS was 91.35% (n=9). The method recoveries meas-
ured with the HQC, MQC and LQC samples were 105.76%, 
106.29% and 99.88% for LPV, respectively. For RTV, the 
method recoveries measured with the HQC, MQC and LQC 
samples were 102.69%, 104.62% and 99.88%, respectively. 
2.6  Stability 
After three freeze-thaw cycles, the changes in the LPV and 
RTV concentrations were less than 10%. The run-time sta-
bility study showed that extracted LPV and RTV were sta-
ble in the autosampler at 20°C for up to 24 h (deviation 
within ±10% compared with the result at 0 h). Long-term 
stability tests of LPV and RTV were in the acceptable range 
(Table 2). 
2.7  Application to human plasma samples 
The baseline characteristics of three Chinese HIV-positive 
patients with normal hepatic and renal function are listed in 
Table 3. Seventeen plasma samples were obtained from 
these patients and sixteen Ctrough of LPV and RTV were de-
termined simultaneously. The mean Ctrough of LPV was 5.90 
µg mL1 (min–max, 3.18–12.66 µg mL1), which was above 
the target cut-off value (Figure 2A). The lowest Ctrough of 
RTV measured using this assay was 0.28 µg mL1, and ap-
proximately six times higher than the LLOQ (Figure 2B). 
The Cmax values for LPV and RTV at week 8 from patient 
#03 were 10.89 and 0.79 µg mL1, respectively. A blood 
sample was not obtained at week 48 from patient #03, 
which meant the plasma concentrations of LPV and RTV 
were not determined.  
3  Discussion 
LPV/r tablets were approved by the U.S. Food and Drug 
Administration in 2005 for use with other antiretroviral 
drugs in the treatment of HIV infection in adults and chil-
dren 6 months of age or older [3]. LPV/r is a major an-
tiretroviral in salvage regimens, has been proven effective 
in Chinese HIV-positive adults with first-line treatment 
failure [46]. The establishment of a quantitative method 
for determination of LPV and RTV in clinical pharmacoki-
netic studies and therapeutic drug monitoring is necessary.  
To date, only a few HPLC methods for simultaneous quan-
tification of LPV and RTV have been developed [1322]. 
Among these methods, some have used solid phase extrac-
tion, which is an expensive and difficult procedure for sam-
ple preparation. Other methods have used a gradient elution 
program, mass spectrometry, and/or diode array detection, 
which require expensive instruments. Because of these rea-
sons, the published methods have had limited use in coun-
tries with limited resources. The current study aimed to  
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(µg mL1) (mean±SD) R.E.C.
a) (%) R.S.D.b) (%) 
LPV        
18 19.45±0.48 108.07 2.48  18.34±0.46 101.91 2.53 
10 10.82±0.23 108.21 2.16  10.31±0.24 103.09 2.34 
1 0.99±0.03 98.92 3.20  1.01±0.04 101.47 4.04 
RTV        
4.5 4.70±0.11 104.40 2.41  4.49±0.01 99.83 0.31 
2.5 2.66±0.07 106.23 2.60  2.55±0.05 101.92 1.83 
0.25 0.25±0.01 98.77 2.12  0.25±0.01 101.74 4.94 
a) R.E.C. (%)=calculated concentration/spiked concentration×100. b) R.S.D. (%)=SD/calculated concentration×100. 
Table 2  Stability tests of LPV and RTV 
















Freeze and thaw (72 h) HQC 17.46±0.54 97.00 3.12  4.26±0.20 94.72 4.76 
 MQC 10.11±0.19 101.09 1.91  2.52±0.03 100.63 1.27 
 LQC 1.00±0.02 100.14 1.77  0.24±0.00 97.90 1.54 
Autosampler (24 h) HQC 18.09±0.32 100.51 1.76  4.49±0.07 99.88 1.49 
 MQC 9.89±0.60 98.87 6.04  2.55±0.11 101.84 4.48 
 LQC 0.94±0.04 94.17 4.55  0.24±0.01 97.60 5.31 
Long term (90 d) HQC 16.87±1.13 93.75 6.69  4.49±0.32 99.73 7.19 
 MQC 9.89±0.14 98.86 1.46  2.51±0.03 100.52 1.07 
 LQC 1.08±0.03 108.28 3.23  0.25±0.01 100.22 2.50 
a) R.E.C. (%)=calculated concentration/spiked concentration×100. b) R.S.D. (%)=SD/calculated concentration×100. 
Table 3  Baseline characteristics of three HIV-positive Chinese patients  
 Patient #01 Patient #02 Patient #03 
Gender Male Female Female 
Age (years) 46 34 41 
Body-mass index (kg m2) 64 48 54 
Route of transmission Blood Heterosexual Heterosexual 
Duration of HIV diagnosis (years) 13 10 10 
HIV-1 RNA (log10c mL
1) 4.41 4.73 3.91 
CD4+ cell count (cells mm3) 155 272 254 
Hepatitis B coinfection No No No 
Hepatitis C coinfection Yes No No 
 
 
Figure 2  Plasma trough concentrations at 48-week follow-up in three patients orally administered LPV/r tablets. A, LPV. B, RTV. (Triangles represent  
patient #01, circles represent patient #02, and squares represent patient #03). 
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establish a simple, sensitive, accurate, and reproducible 
HPLC-UV-Vis method for quantitative determination of 
LPV and RTV in human plasma.  
The developed assay was sensitive and did not require 
any expensive equipment or extra processing steps. The 
LLOQ values were 0.05 µg mL1 for RTV and 0.5 µg mL1 
for LPV. The high sensitivity of this method can be at-
tributed to several factors. The first and the most important 
factor is high recovery of LPV and RTV from the matrices. 
LLE of 200 µL plasma samples was carried out using 1 mL 
of methyl tert-butyl ether, and this provided higher extrac-
tion efficiency than other organic solvent such as ethyl ether, 
ethyl acetate, or methylene chloride. The high sensitivity 
can also be attributed to a lack of background noise in the 
chromatogram and high signal-to-noise ratio. In the mobile 
phase, the phosphate buffer (pH 4.80) showed satisfactory 
separation of LPV and RTV. Careful adjustment of the ratio 
of phosphate buffer to acetonitrile gave a clean baseline 
between the peaks of interest. The final factor contributing 
to the sensitivity was the use of a single wavelength (205 
nm) for detection. This wavelength gave a relatively high 
absorbance compared with other wavelengths. The injection 
volume was only 20 µL, and the LLOQ could be decreased 
by increasing the injection volume if necessary. If we dou-
ble the injection volume, the plasma sample size can be 
halved, which would be very useful in situations when it is 
difficult to obtain blood samples. 
LPV and RTV are both weak bases with very low pKa 
values (<3) and are not ionized at neutral pH values [23]. 
During method development, the retention times of LPV 
and RTV were affected by the pH of the phosphate buffer in 
the mobile phase. When the pH of phosphate buffer was 
below 4.50, endogenous substances from the plasma inter-
fered with detection of LPV and RTV. However, if the pH 
was above 5.00, the two analytes of interest and the IS were 
not separated. A pH of 4.80 was used to prepare the mobile 
phase to obtain suitable retention times and optimize the 
peak shapes of the analytes of interest. 
A gradient elution program is commonly used for deter-
mination of LPV and RTV [13,14,18]. However, this re-
quires binary pump system, a difficult elution procedure, 
long run time, and results in reagent waste. Under isocratic 
conditions in the present study, the run time was short (12 
min) and the analytical column did not need washed or 
re-equilibrated between runs. This condition provided good 
resolutions for the analyte peaks and separated them from 
endogenous interferences in plasma and potential concomi-
tant antiretroviral drugs. Notably, the analytical column did 
not show any deterioration after more than 6 months of use. 
A structural analog of the analyte of interest is an ideal IS 
because it will exhibit similar behavior in the sample ex-
traction, chromatographic elution, and UV detection proce-
dures. Compound A-86093 (Abbott Laboratories, North 
Chicago, IL) is commonly used as the IS [1922,24,25]. 
Unfortunately, A-86093 is not commercially available in 
China. Therefore, we tried to find another compounds for 
use as the IS, and considered diazepam, clonazepam, and 
ranitidine. Diazepam was chosen as the IS because it gave a 
high extraction recovery and suitable retention time. The 
other advantages of diazepam include its low cost, availa-
bility, and the fact it is rarely prescribed to HIV-positive 
patients in China. 
The developed method showed high sensitivity and spec-
ificity, reproducible sample treatment, and had small sample 
size requirements and a simple isocratic elution. It was suc-
cessfully applied to plasma samples from HIV-positive pa-
tients that were orally administered LPV/r tablets. The re-
sults indicated that the range of the calibration curve and 
LLOQ of the assay were sufficient for quantitative deter-
mination of LPV and RTV in human plasma in patients rou-
tinely taking LPV/r tablets. This method could be used for 
routine therapeutic drug monitoring.  
4  Conclusion 
A HPLC-UV-Vis method was developed for quantitative 
determination of LPV and RTV in human plasma. Efficient 
LLE provided excellent sample clean up, high extraction 
efficiency, and high sensitivity with a small sample size. 
The analysis method was specific, accurate, and reproduci-
ble. It was successfully applied to human plasma samples 
from HIV-positive Chinese patients, and was robust and 
reliable. Because this method is simple and inexpensive, it 
could be used in pharmacokinetic studies and routine thera-
peutic drug monitoring of LPV and RTV, especially in re-
source-limited settings. 
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